Eiger BioPharmaceuticals, Inc.
DelistedCIK 1305253fmd_1XY2AQ33GVNSMZ7DNZZ6BJMBBTManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2012 to Dec 31, 2023, 45 periods
Latest annual · FY2023
Millions- Total revenues
- 16
- Gross profit
- 16
- Operating income
- (72)
- Net income
- (75)
- Free cash flow
- (75)
Latest quarter · Q4 FY2023
Millions- Total revenues
- 4
- Gross profit
- 3
- Operating income
- (13)
- Net income
- (13)
- Free cash flow
- (14)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
- Revenue, 5 yearsFY2018 to FY2023
- n/m
- Net income, 5 yearsFY2018 to FY2023
- n/m
Eiger BioPharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $15.8 million | $13.5 million | +17% | 10-K 2024-04-08 · proof |
| Gross profit | $15.7 million | $11.6 million | +35.2% | 10-K 2024-04-08 · proof |
| Operating income | -$71.8 million | -$92.7 million | 10-K 2024-04-08 · proof | |
| Net income | -$75 million | -$96.8 million | 10-K 2024-04-08 · proof | |
| Cash from operating activities | -$74.5 million | -$83 million | 10-K 2024-04-08 · proof | |
| Free cash flow | -$74.8 million | -$83.4 million | 10-K 2024-04-08 · proof | |
| Total assets | $38.8 million | $120.1 million | -67.7% | 10-K 2024-04-08 · proof |
| Total liabilities | $53.3 million | $64.8 million | -17.8% | 10-K 2024-04-08 · proof |
| Cash and cash equivalents | $25.4 million | $25.8 million | -1.4% | 10-K 2024-04-08 · proof |
| Total debt | $41.1 million | $39.6 million | +3.8% | 10-K 2024-04-08 · proof |
- What was Eiger BioPharmaceuticals, Inc.'s revenue in fiscal 2023?
- Eiger BioPharmaceuticals, Inc. reported revenue of $15.8 million for fiscal 2023 (the year ended Dec 31, 2023), against $13.5 million the year before (+17%). Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What was Eiger BioPharmaceuticals, Inc.'s gross profit in fiscal 2023?
- Eiger BioPharmaceuticals, Inc. reported gross profit of $15.7 million for fiscal 2023 (the year ended Dec 31, 2023), against $11.6 million the year before (+35.2%). Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What was Eiger BioPharmaceuticals, Inc.'s operating income in fiscal 2023?
- Eiger BioPharmaceuticals, Inc. reported operating income of -$71.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$92.7 million the year before. Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What was Eiger BioPharmaceuticals, Inc.'s net income in fiscal 2023?
- Eiger BioPharmaceuticals, Inc. reported net income of -$75 million for fiscal 2023 (the year ended Dec 31, 2023), against -$96.8 million the year before. Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What was Eiger BioPharmaceuticals, Inc.'s cash from operating activities in fiscal 2023?
- Eiger BioPharmaceuticals, Inc. reported cash from operating activities of -$74.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$83 million the year before. Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What was Eiger BioPharmaceuticals, Inc.'s free cash flow in fiscal 2023?
- Eiger BioPharmaceuticals, Inc. reported free cash flow of -$74.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$83.4 million the year before. Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What are Eiger BioPharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2023, Eiger BioPharmaceuticals, Inc. reported total assets of $38.8 million, against $120.1 million a year earlier (-67.7%). Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What are Eiger BioPharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2023, Eiger BioPharmaceuticals, Inc. reported total liabilities of $53.3 million, against $64.8 million a year earlier (-17.8%). Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What are Eiger BioPharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Eiger BioPharmaceuticals, Inc. reported cash and cash equivalents of $25.4 million, against $25.8 million a year earlier (-1.4%). Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
- What is Eiger BioPharmaceuticals, Inc.'s total debt?
- As of Dec 31, 2023, Eiger BioPharmaceuticals, Inc. reported total debt of $41.1 million, against $39.6 million a year earlier (+3.8%). Source: the 10-K filed with the SEC on Apr 8, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1305253&period_type=annual&limit=5"Information only, not investment advice.